Canadian LPs anchor Versant Venture Capital VI's $538 mln close
U.S. venture capital firm Versant Ventures has closed its sixth life sciences fund, Versant Venture Capital VI, at its hard-cap target of $538 million (US$400 million). Fund VI, which was oversubscribed, secured commitments from both new and existing limited partners, including Canadian investors Teralys Capital, Northleaf Capital Partners, HarbourVest Canada Growth Fund and Fonds de solidarité FTQ. The fund will invest in up to 25 healthcare companies with an emphasis on novel therapeutics in the United States, Canada and Europe. Versant co-led Canada's largest venture round in 2016, the US$225 million financing of Toronto's BlueRock Therapeutics.
3 January 2017•3 mins read
